QCM Cayman’s BeOne Medicines Ltd ONC Stock Holding History

QCM Cayman’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-758	Closed	-$275K	–	156
2021 Q3	$275K	Buy	+758	New	+$248K	0.75%	58

Other funds holding ONC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

QCM Cayman's ONC Position: Q4 2021 in Review

QCM Cayman sold out of BeOne Medicines Ltd (ONC) in Q4 2021, closing a stake of 758 shares — an estimated $275K sold.

QCM Cayman first reported a position in ONC in Q3 2021 and held it in 1 quarter. The position peaked at $275K in Q3 2021. 262 funds tracked by Wall St. Rank hold ONC as of Q4 2021.

QCM Cayman reported no remaining BeOne Medicines Ltd position as of Q4 2021 after selling out during the quarter.
QCM Cayman sold 758 BeOne Medicines Ltd shares in Q4 2021, an estimated $275K.
QCM Cayman first reported a position in BeOne Medicines Ltd in Q3 2021 and held it in 1 quarter.
QCM Cayman's BeOne Medicines Ltd position peaked at $275K in Q3 2021.
262 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2021.

Based on QCM Cayman's 13F filing for Q4 2021, filed 11 Feb 2022.